BOSTON (CBS.MW) -- Boston Scientific's highly anticipated new cardiovascular stent dramatically reduced the rate of vessel reblockage among heart disease patients who received the device in late-stage clinical testing, the company said Monday.By one measure, patients who received the "drug-coated" stent had reclosure rates of 7.9 percent compared with 26.6 percent for patients who got older "bare" stents,http://www.marketwatch.com/news/yhoo/story.asp?source=blq/yhoo&siteid=yhoo&dist=yhoo&guid=%7BBFE97065%2D37F6%2D4A56%2D95DC%2D75B0BEEA1325%7Dalso:http://biz.yahoo.com/rc/030915/health_bostonscientific_stent_2.html
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra